longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

BIOCYTOGEN-B

02315

58.6003.86% ( -2.350 )
Delay Trading: Sep 10, 09:36:47
Start trading
OverviewOverviewNewsNewsPostsPostsFinancialsFinancialsForecastForecastValuationValuationShareholdersShareholdersProfileProfile
LongbridgeAI

Current ValuationThe current P/E ratio is 64.59, within the reasonable range, cheaper than 43.17% of the time in the past 3 years, and the industry ranks 20/78, the industry Median -5.53.

64.59xP/E
HK$60.95Stock price
HK$0.94Earnings per share
64.59xP/E
Stock priceHK$60.95Earnings per shareHK$0.94

Historical Valuation

P/E ratioTypical rangeMedian
P/E ratio
-5.88x
Typical range
-9.70x–132.55x

Peer P/E ratio Comparison

It displays how the company's P/E ratio compares to top companies within its industry.
0166332498664

The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.

Industry P/E ratio Comparison

This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x30x60x90x120x150x
P/E ratio
Name/Symbol
06160HKBEONE MEDICINES
62.57x202.45%HK$321.72B
02315HKBIOCYTOGEN-B
64.59x108.73%HK$27.24B
06915HKJIANGXI BIO
61.11x--HK$5.09B

Risk Warning

Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.